Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCI-779 in Relapsed/Refractory/Transformed CLL
NCT00086840Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2004
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temsirolimus in chronic lymphocytic leukemia (CLL), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate (CR or PR) at 6 months. Started May 2004; status: terminated.
02
Drugs
temsirolimus
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00086840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086840.